Clinical Trials on Platinum-resistant Advanced Ovarian Cancer

Total 6416 results

Bristol-Myers Squibb

Terminated

A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Advanced Cancer

United States, Netherlands, Australia, Belgium, Canada, Italy, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)

Advanced Cancer
Peter MacCallum Cancer Centre, Australia

Completed

A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours (LeY-CAR-T)

Advanced Cancer

Australia
Onxeo

Completed

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors (DRIIV-1)

Advanced Cancer

France, Belgium
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Advanced Cancer

China
Case Comprehensive Cancer Center

Completed

Online Information and Support for Distance Caregivers

Advanced Cancer

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Advanced Cancer

United States, Canada, Italy, Netherlands, Spain, Israel
Five Prime Therapeutics, Inc.
Parexel

Completed

Safety Study of FP-1039 To Treat Cancer

Advanced Cancer

United States
BeiGene

Completed

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Advanced Cancer

United States, Taiwan, Australia, Korea, Republic of, New Zealand
Bristol-Myers Squibb

Completed

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Advanced Cancer

United States, Belgium, Canada
Bristol-Myers Squibb

Completed

Phase 1 Study of Mesothelin-ADC

Advanced Cancer

Japan
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

Trial of Olaparib in Combination With AZD5363 (ComPAKT) (ComPAKT)

Advanced Cancer

United Kingdom
Eli Lilly and Company

Completed

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Switzerland
Seoul National University Hospital
Asan Medical Center; Ulsan University Hospital; Korea University Anam Hospital; Ewha Womans University Mokdong Hospital and other collaborators

Completed

Efficacy of Self-education Program for Advanced Care Planning(RCT)

Advanced Cancer

Korea, Republic of
Celldex Therapeutics

Completed

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors

Advanced Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Cancer, Advanced
M.D. Anderson Cancer Center

Completed

Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

Advanced Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Sinotecean on Tolerance and Pharmacokinetics

Advanced Cancer

China
Shenyang Pharmaceutical University

Unknown

Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients

Advanced Cancer

China
Duke University
National Cancer Institute (NCI)

Completed

Intervention Study of Communication in Oncologist-Patient Encounters (COPE)

Advanced Cancer

United States
Alaunos Therapeutics

Completed

Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans

Advanced Cancer

United States
M.D. Anderson Cancer Center

Completed

The Role of the EKG in Anticancer Drug Development

Advanced Cancer

United States
Alaunos Therapeutics

Completed

Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors

Advanced Cancer

United States
Alaunos Therapeutics

Suspended

Study of Oral Palifosfamide Tris in Solid Tumors

Advanced Cancer
Australian and New Zealand Urogenital and Prostate...
Peter MacCallum Cancer Centre, Australia

Recruiting

Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (GUIDE)

Castration Resistant Prostatic Cancer

Australia
University of Cologne
University Hospital Tuebingen; University Hospital Freiburg; Universitätsklinikum... and other collaborators

Unknown

Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci (CONTROL)

Cancer | Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)
British Columbia Cancer Agency
Genome British Columbia; BC Cancer Foundation

Unknown

Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care

Metastatic Cancer | Advanced Cancer | Cancers That Cannot be Treated With Curative Intent
Cairo University

Not yet recruiting

Correlation of Insulin Resistance With Hormonal and Ovarian Morphological Characteristics in Patients With Polycystic Ovarian Syndrome

Study the Relationship Between Insulin Resistance With Hormonal and Ovarian Morphological Characteristics in Patients With Polycystic Ovarian Syndrome
Memorial Sloan Kettering Cancer Center

Recruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Stage III Fallopian Tube Cancer | Stage II Ovary Cancer | Stage II Ovarian Cancer | Stage III Ovary Cancer and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Clear Cell Tumor | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian... and other conditions
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Avera McKennan Hospital & University Health Center

Completed

Identifying Molecular Drivers of Cancer

Cancer | Advanced Cancer | Tumor

United States
British Columbia Cancer Agency
Sanofi; Ozmosis Research Inc.

Unknown

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostatic Cancer

Canada, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Research Study in Patients With Advanced Ovarian Epithelial Cancer

Ovarian Serous Cystadenocarcinoma | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Ovarian Serous Surface Papillary Adenocarcinoma

United States
Dana-Farber Cancer Institute

Recruiting

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Ovarian Cancer | Endometrial Cancer | Ovarian Carcinoma | Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer Stage 3 | Endometrial Cancer Stage

United States
AVEO Pharmaceuticals, Inc.

Completed

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Advanced Cancer | Refractory Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

HIV Infection | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Advanced... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditions

United States
Janssen Research & Development, LLC

Completed

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Neoplasms | Neoplasms, Breast | Neoplasms, Ovarian | Advanced or Refractory Solid Malignancies

United States, United Kingdom, Spain, Belgium
NantCell, Inc.

Terminated

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Sarcoma | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Metastatic Cancer | Solid Tumors | Locally Advanced
Roswell Park Cancer Institute
National Cancer Institute (NCI); Sanofi Pasteur, a Sanofi Company

Completed

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Clear... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
University of Minnesota

Completed

Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Fallopian Tube Cancer | Recurrent Ovarian Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer

Canada
University of Washington
National Cancer Institute (NCI)

Terminated

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer and other conditions

United States
National Cancer Institute (NCI)

Completed

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Stage III Vaginal Cancer | Stage IVA Cervical Cancer | Stage IVA Vaginal Cancer | Stage IVB Cervical Cancer | Stage IVB Vaginal Cancer | Stage IIIA Ovarian... and other conditions

United States
Life Research Technologies GmbH

Unknown

Safety of Active Immunotherapy in Subjects With Ovarian Cancer

Ovarian Epithelial Cancer

Austria, Hungary
Valerio Therapeutics

Recruiting

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Breast Cancer | Prostate Cancer | Advanced or Metastatic Solid Tumors | Recurrent Ovarian Cancer

United States

Clinical Trials on Platinum-resistant Advanced Ovarian Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations